Efficacy and safety of simeprevir with pegylated interferon alfa-2b and ribavirin in kidney transplant patients with chronic hepatitis C

Efficacy and safety of simeprevir with pegylated interferon alfa-2b and ribavirin in kidney transplant patients with chronic hepatitis C - Efficacy and safety of simeprevir with pegylated interferon alfa-2b and ribavirin in kidney transplant patients with chronic hepatitis C

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013088

Enrollment

Registered

2014-02-06

Start date

2014-02-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with chronic hepatitis C virus infection

Interventions

Simeprevir with pegylated interferon alfa and ribavirin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with 20-70 years of age 2) Naive patients with HCV egnotype 1 with viral load of more than 5 log IU/ml 3) Treatment-experienced patients with HCV egnotype 1 4) Eligible patients for interferon and ribavirin

Exclusion criteria

Exclusion criteria: 1) Co-infection with hepatitis B virus 2) Co-infection with anti-human immunodeficiency virus 3) Other forms of liver disease (alcohol liver disease, autoimmune hepatitis etc.) 4) Decompensated cirrhosis, Liver failure 5) Contraindication to pegylated interferon 6) Contraindication to ribavirin

Design outcomes

Primary

Measure	Time frame
Sustained virologic response rate 12(SVR12)	—

Countries

Japan

Contacts

Public ContactNaotsugu Ichimaru

Osaka University Graduate School of Medicine Department of Advanced Technology for Transplantation

ichimaru@att.med.osaka-u.ac.jp06-6879-3746

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026